A Phase 2 Multi-Centre Study to Characterise the Pharmacodynamics of Vessel Dilator Peptide (VSDL) in Patients with Acute Decompensated Congestive Heart Failure to be assessed by effects on renal function.
South Australian Health and Medical Research Institute
65 participants
Aug 7, 2014
Interventional
Conditions
Summary
The CONTINUUM-HF study aims to evaluate whether vessel dilator peptide VSDL has effects on renal function in participants with acute decompensated congestive heart failure. It shall also evaluate the tolerability and safety of VSDL over 7 day dosing, and assess the pharmacodynamics of VSDL in these participants. The study is a multi-centre, blinded, randomised, placebo-controlled, multi-dose study to be conducted in 8 sites in Australia targeting two target peak concentrations following 1-hour intravenous bolus and daily 12-hour subcutaneous infusions for up to 7 days. The target plasma VSDL concentrations of 5ng/ml and 20ng/ml are chosen to reflect well tolerated and efficacious concentrations in previous trials using this drug. Study subjects shall be reviewed post-IV infusion, at 72 hours, pre-discharge, and at 30 days. A 6 month followup contact will be made via phone call or email. Participants will be given a diary to record any adverse events, changes in medication and visits to doctors.
Eligibility
Inclusion Criteria7
- Patients who are hospitalised with acute decompensated congestive heart failure and
- LVEF = 45% and
- GFR 25-90 mls/min as assessed by Cockcroft and Gault and
- NTproBNP > 1000pg/mL and
- Must be able to be hospitalised for a further 72 hours post-IV infusion.
- Non-pregnant females
- Signed Informed consent
Exclusion Criteria8
- Acute ST elevation myocardial infarction (STEMI)
- Pulmonary embolism (PE)
- Severe valvular heart disease
- B/P < 90mm Hg.
- Congenital heart defects
- Cardiac surgery within 4 weeks
- Cerebrovascular accident within 4 weeks
- Presence of hepatic impairment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The study medication is Human pro-ANP (31-67). Participants will be randomised into one of three groups. For the 1 hour intravenous infusion the two drug groups will receive the same dose of drug 100ng/kg/min. The subcutaneous infusion dosing of 12 hours on and 12 hours off is for a minimum of three days and a maximum of six days. Group A-Placebo as described below in the Comparator / control treatment field Group B- Low dose will receive 450 ug/hr for the first 5 hours and then 135 ug/hr for the next 7 hours. Group C-High dose will receive 1800 ug/hr for the first 5 hours and then 540 ug/hr for the next 7 hours. Close monitoring will occur using adverse event monitoring, vital signs including ECG monitoring,vital signs, urine volume and fluid input monitoring, physical examinations and laboratory assessments. As all study drug is administered in hospital this allows for greater compliance and closer monitoring. Follow up is at 30 days by a clinic visit and a 6 month follow up phone call.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001060730